67 (91.8%) trials reported the efficacy standard, but 51 (69.9%) out of 73 trials used composite outcome measure which categorized the effect of the treatment into four grades (cured, markedly effective, effective, ineffective) according to the change of the symptoms, the remaining 16 trials (21.9%) used single outcome measure for therapeutic effect.
The efficacy was evaluated as completely headache free, markedly effective (attack reduction >75%), effective (reduction >50%) or invalid (reduction <50%).
22 of 50 patients reported markedly effective relief of symptoms, 15 cases reported effective relief, and 13 cases reported ineffective relief, with a total of 74% of patients reporting a relief of their symptoms (markedly effective + effective).
In this study, the combined treatment was markedly effective in vivo, but not in vitro.
Surprisingly, application of twice the dose of the 20 G OM 500 mL treatment with the alkylsilicone surfactant (i.e. 1,000 vs. 500 mL) was markedly less effective for both species than the lower dose.
At stopping, the after-treatment syndrome integral were 5.5 ± 2.1 for IFCA group and 6.3 ± 2.3 for IFCS group, the cure-markedly effective rates were 67% for IFCA group and 45% for IFCS group, the one-sided p-value was 0.0036, the median unbiased estimate of the odds ratio (OR) for the benefit of IFCA relative to IFCS was 2.91 with 95%CI: 1.40 to 6.06.
Before the trial was initiated, the sample size was calculated according to the following hypotheses: based on the results of our previous study, we anticipated that the cure-markedly effective rates were 40% for IFCS group and 55% for IFCA group, respectively, and the type I and II error rates were chosen at their usual values of 0.05 (one-sided).
At the third interim analysis, the sample path crossed the upper boundary and the trial was stopped, the cure-markedly effective rates were 45% for IFCS group and 67% for IFCA group, respectively, the one-sided p-value was 0.0036, the median unbiased estimate of the odds ratio (OR) for the benefit of IFCA relative to IFCS was 2.91 with 95%CI: 1.40 to 6.06.
The number of repeats in STR markers differs markedly among individuals, which make them effective for human identification purposes.
In comparison, efforts to design molecular semiconductors based on isoindigo by incorporating electron-rich substitutions, such as benzofuran, aniline, and thiophene derivatives have unfortunately not resulted in markedly more effective donor compounds for OPVs where the PCE has remained around 2% in the absence of any additives.
